23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › Theravance Biopharma, Inc. › 2025-2026

Theravance Biopharma, Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Theravance Biopharma, Inc.’s Form 8-K, filed June 12, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 8Ballot items
  • 214Asset managers, any item
  • 1,868Fund votes
  • June 12, 2026Meeting date

Results at a glance

Meeting of June 12, 2026: 8 items on Theravance Biopharma, Inc.’s Form 8-K, filed June 12, 2026: 6 elected · 2 approved.

Dissent

No notable dissent.

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Theravance Biopharma, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Theravance Biopharma, Inc.

These tallies are Theravance Biopharma, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 12, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Theravance Biopharma, Inc. — official shareholder meeting results, meeting held June 12, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Laurie Smaldone Alsup 42,725,649124,18753,867 --4,156,175 99.7%Elected—
Elect Director: Susannah Gray 42,231,530618,30653,867 --4,156,175 99%Elected—
Elect Director: Dean J. Mitchell 42,557,257297,31649,130 --4,156,175 99.3%Elected—
Elect Director: Donal O'Connor 42,535,463319,11049,130 --4,156,175 99.3%Elected—
Elect Director: Deepika R. Pakianathan 41,936,019918,54349,141 --4,156,175 98%Elected—
Elect Director: Rick E Winningham 42,474,538377,27451,891 --4,156,175 99.1%Elected—
Based on the following results of voting, the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 46,471,340572,89615,642 ---- 99%Approved—
Based on the following results of voting, a non-binding advisory resolution regarding the compensation of the Company's named executive officers 42,631,324221,19651,183 --4,156,175 99.5%Approved—

Source: Theravance Biopharma, Inc., Form 8-K, filed with the SEC on June 12, 2026 — read the filing on EDGAR.

How asset managers voted at the Theravance Biopharma, Inc. 2025-2026 meeting

214 asset managers disclosed a vote on at least one Theravance Biopharma, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Dean J. Mitchell

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

99.3% Majority: yes · of votes cast

FOR 99.3%
FOR: 42,557,257AGAINST: 297,316
Details: description as filed, official tally, votes by 68 asset managers

Description as filed by funds: Elect the following directors to serve as members of the board of directors until the annual general meeting held in 2027 and until their successors are duly elected and qualified: Dean J. Mitchell

Theravance Biopharma, Inc.’s own tally for this item (“Elect Director: Dean J. Mitchell”): 42,557,257 for, 297,316 against, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal One – Based on the following results of voting, the nominees listed below were elected directors to serve as members of the Board until the Company's Annual General Meeting held in 2027 and until their successors are duly elected and qualified:”
Support: 99.3% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 68 asset managers below reported 8,429,312 for, 7,544 against, 11,536 abstained.

FOR
FOR: 8,429,312AGAINST: 7,544ABSTAIN: 11,536
Largest asset managers voting on “Elect the following directors to serve as members of the board of directors until the annual general meeting h” at Theravance Biopharma, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard2,161,4063,444 00For
BlackRock2,060,6910 00For
Fidelity972,6820 00For
Janus Detroit Street Trust350,6370 00For
Charles Schwab309,5630 00For
Pacer Funds Trust292,5860 00For
Invesco237,7580 00For
Dimensional231,1990 00For
State Street213,5600 00For
Delaware/Macquarie208,7830 00For
SEI198,5320 00For
American Century117,9020 00For
Equitable112,9030 00For
TIAA88,3510 00For
Goldman Sachs66,1030 00For
QUANTITATIVE MASTER SERIES LLC61,5470 00For
EA Series Trust55,1270 00For
Principal Exchange-Traded Funds50,4400 00For
Lincoln Financial50,3250 00For
Legg Mason47,3550 00For
Global X42,7040 00For
MASTER INVESTMENT PORTFOLIO42,7040 00For
ALPS ETF Trust41,2560 00For
Prudential/PGIM34,1800 00For
Northern Trust33,6160 00For

Showing the 25 largest of 68 asset managers. All 68 are in the interactive database (link above).

Elect Director: Deepika R. Pakianathan

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%
FOR: 41,936,019AGAINST: 918,543
Details: description as filed, official tally, votes by 68 asset managers

Description as filed by funds: Elect the following directors to serve as members of the board of directors until the annual general meeting held in 2027 and until their successors are duly elected and qualified: Deepika R. Pakianathan

Theravance Biopharma, Inc.’s own tally for this item (“Elect Director: Deepika R. Pakianathan”): 41,936,019 for, 918,543 against, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal One – Based on the following results of voting, the nominees listed below were elected directors to serve as members of the Board until the Company's Annual General Meeting held in 2027 and until their successors are duly elected and qualified:”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 68 asset managers below reported 8,188,650 for, 248,206 against, 11,536 abstained.

FOR
FOR: 8,188,650AGAINST: 248,206ABSTAIN: 11,536
Largest asset managers voting on “Elect the following directors to serve as members of the board of directors until the annual general meeting h” at Theravance Biopharma, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard2,161,4043,446 00For
BlackRock2,060,6910 00For
Fidelity972,6820 00For
Janus Detroit Street Trust350,6370 00For
Charles Schwab309,5630 00For
Pacer Funds Trust292,5860 00For
Invesco237,7580 00For
Dimensional231,1990 00For
State Street0213,560 00Against
Delaware/Macquarie208,7830 00For
SEI198,5320 00For
American Century117,9020 00For
Equitable112,9030 00For
TIAA88,3510 00For
Goldman Sachs66,1030 00For
QUANTITATIVE MASTER SERIES LLC61,5470 00For
EA Series Trust55,1270 00For
Principal Exchange-Traded Funds50,4400 00For
Lincoln Financial24,32526,000 00Mixed
Legg Mason47,3550 00For
Global X42,7040 00For
MASTER INVESTMENT PORTFOLIO42,7040 00For
ALPS ETF Trust41,2560 00For
Prudential/PGIM34,1800 00For
Northern Trust33,6160 00For

Showing the 25 largest of 68 asset managers. All 68 are in the interactive database (link above).

Elect Director: Donal O'Connor

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 4 wordings of this item as funds reported it.

99.3% Majority: yes · of votes cast

FOR 99.3%
FOR: 42,535,463AGAINST: 319,110

Prior year: 99.5% for (May 19, 2025 meeting) ▼ 0.3 pts

Details: description as filed, official tally, votes by 68 asset managers

Description as filed by funds: Elect the following directors to serve as members of the board of directors until the annual general meeting held in 2027 and until their successors are duly elected and qualified: Donal O'Connor

Theravance Biopharma, Inc.’s own tally for this item (“Elect Director: Donal O'Connor”): 42,535,463 for, 319,110 against, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal One – Based on the following results of voting, the nominees listed below were elected directors to serve as members of the Board until the Company's Annual General Meeting held in 2027 and until their successors are duly elected and qualified:”
Support: 99.3% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 68 asset managers below reported 8,431,518 for, 5,337 against, 11,536 abstained.

FOR
FOR: 8,431,518AGAINST: 5,337ABSTAIN: 11,536
Largest asset managers voting on “Elect the following directors to serve as members of the board of directors until the annual general meeting h” at Theravance Biopharma, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard2,159,7285,121 00For
BlackRock2,060,6910 00For
Fidelity972,6820 00For
Janus Detroit Street Trust350,6370 00For
Charles Schwab309,5630 00For
Pacer Funds Trust292,5860 00For
Invesco237,7580 00For
Dimensional231,1990 00For
State Street213,5600 00For
Delaware/Macquarie208,7830 00For
SEI198,5320 00For
American Century117,9020 00For
Equitable112,9030 00For
TIAA88,3510 00For
Goldman Sachs66,1030 00For
QUANTITATIVE MASTER SERIES LLC61,5470 00For
EA Series Trust55,1270 00For
Principal Exchange-Traded Funds50,4400 00For
Lincoln Financial50,3250 00For
Legg Mason47,3550 00For
Global X42,7040 00For
MASTER INVESTMENT PORTFOLIO42,7040 00For
ALPS ETF Trust41,2560 00For
Prudential/PGIM34,1800 00For
Northern Trust33,6160 00For

Showing the 25 largest of 68 asset managers. All 68 are in the interactive database (link above).

Elect Director: Laurie Smaldone Alsup

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

99.7% Majority: yes · of votes cast

FOR 99.7%
FOR: 42,725,649AGAINST: 124,187
Details: description as filed, official tally, votes by 68 asset managers

Description as filed by funds: Elect the following directors to serve as members of the board of directors until the annual general meeting held in 2027 and until their successors are duly elected and qualified: Laurie Smaldone Alsup

Theravance Biopharma, Inc.’s own tally for this item (“Elect Director: Laurie Smaldone Alsup”): 42,725,649 for, 124,187 against, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal One – Based on the following results of voting, the nominees listed below were elected directors to serve as members of the Board until the Company's Annual General Meeting held in 2027 and until their successors are duly elected and qualified:”
Support: 99.7% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 68 asset managers below reported 8,430,122 for, 6,734 against, 11,536 abstained.

FOR
FOR: 8,430,122AGAINST: 6,734ABSTAIN: 11,536
Largest asset managers voting on “Elect the following directors to serve as members of the board of directors until the annual general meeting h” at Theravance Biopharma, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard2,161,4063,444 00For
BlackRock2,060,6910 00For
Fidelity972,6820 00For
Janus Detroit Street Trust350,6370 00For
Charles Schwab309,5630 00For
Pacer Funds Trust292,5860 00For
Invesco237,7580 00For
Dimensional231,1990 00For
State Street213,5600 00For
Delaware/Macquarie208,7830 00For
SEI198,5320 00For
American Century117,9020 00For
Equitable112,9030 00For
TIAA88,3510 00For
Goldman Sachs66,1030 00For
QUANTITATIVE MASTER SERIES LLC61,5470 00For
EA Series Trust55,1270 00For
Principal Exchange-Traded Funds50,4400 00For
Lincoln Financial50,3250 00For
Legg Mason47,3550 00For
Global X42,7040 00For
MASTER INVESTMENT PORTFOLIO42,7040 00For
ALPS ETF Trust41,2560 00For
Prudential/PGIM34,1800 00For
Northern Trust33,6160 00For

Showing the 25 largest of 68 asset managers. All 68 are in the interactive database (link above).

Elect Director: Rick E Winningham

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

99.1% Majority: yes · of votes cast

FOR 99.1%
FOR: 42,474,538AGAINST: 377,274

Prior year: 93.6% for (May 19, 2025 meeting) ▲ 5.6 pts

Details: description as filed, official tally, votes by 68 asset managers

Description as filed by funds: Elect the following directors to serve as members of the board of directors until the annual general meeting held in 2027 and until their successors are duly elected and qualified: Rick E Winningham

Theravance Biopharma, Inc.’s own tally for this item (“Elect Director: Rick E Winningham”): 42,474,538 for, 377,274 against, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal One – Based on the following results of voting, the nominees listed below were elected directors to serve as members of the Board until the Company's Annual General Meeting held in 2027 and until their successors are duly elected and qualified:”
Support: 99.1% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 68 asset managers below reported 8,433,196 for, 3,660 against, 11,536 abstained.

FOR
FOR: 8,433,196AGAINST: 3,660ABSTAIN: 11,536
Largest asset managers voting on “Elect the following directors to serve as members of the board of directors until the annual general meeting h” at Theravance Biopharma, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard2,161,4063,444 00For
BlackRock2,060,6910 00For
Fidelity972,6820 00For
Janus Detroit Street Trust350,6370 00For
Charles Schwab309,5630 00For
Pacer Funds Trust292,5860 00For
Invesco237,7580 00For
Dimensional231,1990 00For
State Street213,5600 00For
Delaware/Macquarie208,7830 00For
SEI198,5320 00For
American Century117,9020 00For
Equitable112,9030 00For
TIAA88,3510 00For
Goldman Sachs66,1030 00For
QUANTITATIVE MASTER SERIES LLC61,5470 00For
EA Series Trust55,1270 00For
Principal Exchange-Traded Funds50,4400 00For
Lincoln Financial50,3250 00For
Legg Mason47,3550 00For
Global X42,7040 00For
MASTER INVESTMENT PORTFOLIO42,7040 00For
ALPS ETF Trust41,2560 00For
Prudential/PGIM34,1800 00For
Northern Trust33,6160 00For

Showing the 25 largest of 68 asset managers. All 68 are in the interactive database (link above).

Elect Director: Susannah Gray

Official resultDIRECTOR ELECTIONSReported outcome: Elected

Combines 3 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%
FOR: 42,231,530AGAINST: 618,306

Prior year: 99.7% for (May 19, 2025 meeting) ▼ 1.2 pts

Details: description as filed, official tally, votes by 68 asset managers

Description as filed by funds: Elect the following directors to serve as members of the board of directors until the annual general meeting held in 2027 and until their successors are duly elected and qualified: Susannah Gray

Theravance Biopharma, Inc.’s own tally for this item (“Elect Director: Susannah Gray”): 42,231,530 for, 618,306 against, per its Form 8-K filed June 12, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal One – Based on the following results of voting, the nominees listed below were elected directors to serve as members of the Board until the Company's Annual General Meeting held in 2027 and until their successors are duly elected and qualified:”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 68 asset managers below reported 8,226,395 for, 210,461 against, 11,536 abstained.

FOR
FOR: 8,226,395AGAINST: 210,461ABSTAIN: 11,536
Largest asset managers voting on “Elect the following directors to serve as members of the board of directors until the annual general meeting h” at Theravance Biopharma, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard2,163,1721,678 00For
BlackRock2,060,6910 00For
Fidelity972,6820 00For
Janus Detroit Street Trust350,6370 00For
Charles Schwab309,5630 00For
Pacer Funds Trust292,5860 00For
Invesco237,7580 00For
Dimensional231,1990 00For
State Street213,5600 00For
Delaware/Macquarie0208,783 00Against
SEI198,5320 00For
American Century117,9020 00For
Equitable112,9030 00For
TIAA88,3510 00For
Goldman Sachs66,1030 00For
QUANTITATIVE MASTER SERIES LLC61,5470 00For
EA Series Trust55,1270 00For
Principal Exchange-Traded Funds50,4400 00For
Lincoln Financial50,3250 00For
Legg Mason47,3550 00For
Global X42,7040 00For
MASTER INVESTMENT PORTFOLIO42,7040 00For
ALPS ETF Trust41,2560 00For
Prudential/PGIM34,1800 00For
Northern Trust33,6160 00For

Showing the 25 largest of 68 asset managers. All 68 are in the interactive database (link above).

Based on the following results of voting, a non-binding advisory resolution regarding the compensation of the Company's…

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 5 wordings of this item as funds reported it.

99.5% Approved · of votes cast

FOR 99.5%
FOR: 42,631,324AGAINST: 221,196
Details: description as filed, official tally, votes by 214 asset managers

Description as filed by funds: Approve the non-binding advisory resolution regarding the compensation of our named executive officers.

Theravance Biopharma, Inc.’s own tally for this item (“Proposal Three – Based on the following results of voting, a non-binding advisory resolution regarding the compensation of the Company's named executive officers was approved:”): 42,631,324 for, 221,196 against — passed, per its Form 8-K filed June 12, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal Three – Based on the following results of voting, a non-binding advisory resolution regarding the compensation of the Company's named executive officers was approved:”
Support: 99.5% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 68 asset managers voting on “Approve the non-binding advisory resolution regarding the compensation of our named executive officers.” at Theravance Biopharma, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard2,164,8500 00For
BlackRock2,060,6910 00For
Fidelity972,6820 00For
Janus Detroit Street Trust350,6370 00For
Charles Schwab309,5630 00For
Pacer Funds Trust292,5860 00For
Invesco237,7580 00For
Dimensional231,1990 00For
State Street213,5600 00For
Delaware/Macquarie208,7830 00For
SEI198,5320 00For
American Century117,9020 00For
Equitable112,9030 00For
TIAA88,3510 00For
Goldman Sachs66,1030 00For
QUANTITATIVE MASTER SERIES LLC61,5470 00For
EA Series Trust55,1270 00For
Principal Exchange-Traded Funds50,4400 00For
Lincoln Financial50,3250 00For
Legg Mason47,3550 00For
Global X42,7040 00For
MASTER INVESTMENT PORTFOLIO42,7040 00For
ALPS ETF Trust41,2560 00For
Prudential/PGIM34,1800 00For
Northern Trust33,6160 00For

Fund voting reports, all 68 managers: 8,438,740 for, 11,536 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 166 asset managers voting on “Approve the non-binding advisory resolution regarding the compensation of our named executive officers.” at Theravance Biopharma, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Madison Avenue Partners, LP8,944,6050 00For
Newtyn Management, LLC4,036,2180 00For
Irenic Capital Management LP2,566,1960 00For
BlackRock1,599,3910 00For
GEODE CAPITAL MANAGEMENT, LLC965,1250 00For
Weiss Asset Management LP765,6110 00For
State Street729,4236,939 00For
Janus Henderson719,6320 00For
DE Shaw673,3820 00For
ACADIAN ASSET MANAGEMENT LLC558,0770 00For
Two Sigma454,8310 00For
Vanguard314,5310 00For
Charles Schwab310,9980 00For
683 Capital Management, LLC250,0000 00For
MACKENZIE FINANCIAL CORP248,6820 00For
Northern Trust208,5741,556 00For
NOMURA INVESTMENT MANAGEMENT BUSINESS TRUST208,7830 00For
SEI200,0740 00For
Connor, Clark & Lunn Investment Management Ltd.185,4560 00For
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP167,1020 00For
Fidelity123,8860 00For
STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM123,5820 00For
American Century117,9020 00For
T. Rowe Price112,6260 00For
Prudential/PGIM104,6822,600 00For

Institutional-manager reports, all 166 managers: 26,433,247 for, 99,669 against, 1,741 abstained, 1,214 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Based on the following results of voting, the appointment of Ernst & Young LLP as the Company's independent registered…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

99% Approved · of votes cast

FOR 99%
FOR: 46,471,340AGAINST: 572,896
Details: description as filed, official tally, votes by 69 asset managers

Description as filed by funds: Ratify the appointment of Ernst & Young LLP as Theravance Biopharma, Inc.'s independent registered public accounting firm for the fiscal year ending December 31, 2026.

Theravance Biopharma, Inc.’s own tally for this item (“Proposal 2: Based on the following results of voting, the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified”): 46,471,340 for, 572,896 against — passed, per its Form 8-K filed June 12, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal Two – Based on the following results of voting, the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified:”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 69 asset managers below reported 8,432,892 for, 6,401 against, 11,536 abstained.

FOR
FOR: 8,432,892AGAINST: 6,401ABSTAIN: 11,536
Largest asset managers voting on “Ratify the appointment of Ernst & Young LLP as Theravance Biopharma, Inc.'s independent registered public acco” at Theravance Biopharma, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard2,164,8491 00For
BlackRock2,060,6910 00For
Fidelity972,6820 00For
Janus Detroit Street Trust350,6370 00For
Charles Schwab309,5630 00For
Pacer Funds Trust292,5860 00For
Invesco237,7580 00For
Dimensional231,1990 00For
State Street213,5600 00For
Delaware/Macquarie208,7830 00For
SEI198,5320 00For
American Century117,9020 00For
Equitable112,9030 00For
TIAA88,3510 00For
Goldman Sachs66,1030 00For
QUANTITATIVE MASTER SERIES LLC61,5470 00For
EA Series Trust55,1270 00For
Principal Exchange-Traded Funds50,4400 00For
Lincoln Financial50,3250 00For
Legg Mason47,3550 00For
Global X42,7040 00For
MASTER INVESTMENT PORTFOLIO42,7040 00For
ALPS ETF Trust41,2560 00For
Prudential/PGIM34,1800 00For
Northern Trust33,6160 00For

Showing the 25 largest of 69 asset managers. All 69 are in the interactive database (link above).

Largest Theravance Biopharma, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 51,515,000 shares outstanding at the time of that meeting.

Fund voting reports: top Theravance Biopharma, Inc. shareholders by shares voted on “Approve the non-binding advisory resolution regarding the compensation of our named executive…”, 2025-2026
#Asset manager % of shares outstanding
1Vanguard 4.20%
2BlackRock 4.00%
3Fidelity 1.89%
4Janus Detroit Street Trust 0.68%
5Charles Schwab 0.60%
6Pacer Funds Trust 0.57%
7Invesco 0.46%
8Dimensional 0.45%
9State Street 0.41%
10Delaware/Macquarie 0.41%
Institutional-manager reports: top Theravance Biopharma, Inc. shareholders by shares voted on “Approve the non-binding advisory resolution regarding the compensation of our named executive…”, 2025-2026
#Asset manager % of shares outstanding
1Madison Avenue Partners, LP 17.36%
2Newtyn Management, LLC 7.84%
3Irenic Capital Management LP 4.98%
4BlackRock 3.10%
5GEODE CAPITAL MANAGEMENT, LLC 1.87%
6Weiss Asset Management LP 1.49%
7State Street 1.43%
8Janus Henderson 1.40%
9DE Shaw 1.31%
10ACADIAN ASSET MANAGEMENT LLC 1.08%

Reported Theravance Biopharma, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Theravance Biopharma, Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Madison Avenue Partners, LP9,511,150 18.46%Proxy statement (DEF 14A), table as of April 13, 2026
Madison Avenue International LP9,212,252 17.88%Schedule 13G, filed August 14, 2026
Weiss Asset Management LP7,457,060 14.48%Proxy statement (DEF 14A), table as of April 13, 2026
BlackRock4,296,290 8.34%Form 13F, quarter ended March 31, 2026
Newtyn Management, LLC3,434,191 6.67%Schedule 13G, filed August 14, 2026
Irenic Capital Management LP2,760,948 5.36%Proxy statement (DEF 14A), table as of April 13, 2026
Vanguard Group2,367,353 4.60%Form 13F, quarter ended March 31, 2026
Rick E Winningham2,013,938 3.91%Proxy statement (DEF 14A), table as of April 13, 2026
State Street1,297,323 2.52%Form 13F, quarter ended March 31, 2026
Two Sigma1,258,497 2.44%Form 13F, quarter ended March 31, 2026

Percentages above are of 51,515,000 shares outstanding, as reported by Theravance Biopharma, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Theravance Biopharma, Inc.'s shareholder meeting held June 12, 2026, in the 2025-2026 proxy season, 214 asset managers reported votes on at least one of its 8 ballot items in their SEC Form N-PX filings, covering 1,868 separate fund positions. On the most widely held item on that ballot — Approve the non-binding advisory resolution regarding the compensation of our named executive… — Theravance Biopharma, Inc.'s filing reports the proposal as approved, with 99.5% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Theravance Biopharma, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 12, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Theravance Biopharma, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Theravance Biopharma, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “Theravance Biopharma, Inc. 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/theravance-biopharma-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.